MCID: SRS001
MIFTS: 60

Serous Cystadenocarcinoma malady

Cancer diseases category

Summaries for Serous Cystadenocarcinoma

About this section
Sources:
9Disease Ontology, 66Wikipedia, 34MalaCards
See all sources

Fully expand this MalaCard

Download this MalaCard
Disease Ontology:9 A cystadenocarcinoma that derives from epithelial cells originating in glandular tissue forming serous lesions.

MalaCards: Serous Cystadenocarcinoma, also known as serous cystadenocarcinoma, nos, is related to cystadenocarcinoma and ovarian serous cystadenocarcinoma. An important gene associated with Serous Cystadenocarcinoma is BIRC5 (baculoviral IAP repeat containing 5), and among its related pathways are Ovarian Infertility Genes and Plasma membrane estrogen receptor signaling. The compounds tanshinone iia and toremifene have been mentioned in the context of this disorder. Affiliated tissues include ovary, pancreas and colon, and related mouse phenotypes are pigmentation and hearing/vestibular/ear.

Wikipedia:66 Serous cystadenocarcinoma is a type of tumor in the cystadenocarcinoma grouping. more...

Aliases & Classifications for Serous Cystadenocarcinoma

About this section
Sources:
9Disease Ontology, 11DISEASES, 46Novoseek, 63UMLS, 41NCIt, 59SNOMED-CT, 36MeSH
See all sources

Classifications:

Malacards categories (disease lists): (See all malacards categories)
Global: Cancer diseases


Aliases & Descriptions:

serous cystadenocarcinoma 9 11
serous cystadenocarcinoma, nos 9
cystadenocarcinoma, serous 63
cystadenocarcinoma serous 46
serous adenocarcinoma 9
serous carcinoma 9


External Ids:

Disease Ontology9 DOID:3114
SNOMED-CT59 189685001, 90725004
MeSH36 D018284

Related Diseases for Serous Cystadenocarcinoma

About this section
Sources:
18GeneCards, 19GeneDecks
See all sources

Diseases related to Serous Cystadenocarcinoma via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show top 50)    (show all 158)
idRelated DiseaseScoreTop Affiliating Genes
1cystadenocarcinoma31.9MUC16
2ovarian serous cystadenocarcinoma31.3UBE4A, ZNF217, MUC16, USP2, USP14
3adenocarcinoma31.0ESR1, ESR2, PGR, TP53, VEGFA, MUC16
4adenofibroma30.4MUC16
5leiomyosarcoma30.3MUC16, PGR, TP53
6bilateral breast cancer30.2ESR1, PGR
7endometriosis30.2CYP19A1, VEGFA, PGR, ESR2, ESR1, MUC16
8endometrial carcinoma30.2TP53, PGR, ESR2, ESR1, MUC16, BCL2
9lymphangioleiomyomatosis30.1PGR, ESR1
10angiomyolipoma30.1PGR, ESR1
11breast cancer30.1CYP19A1, PGR, ESR2, ESR1, AKT1
12malignant mixed mullerian tumor30.1TP53, PGR
13leiomyoma30.0CYP19A1, PGR, ESR2, ESR1
14leukemia30.0TP53, ESR2, FAS, AKT1, BCL2, BIRC5
15astrocytoma30.0VEGFA, TP53, AKT1, CDKN1A
16transitional cell carcinoma30.0TP53, MUC16, BIRC5, CDKN1A
17melanoma29.7VEGFA, TP53, FAS, AKT1, BCL2, BIRC5
18ovarian cancer29.6MUC16, ESR1, ESR2, PGR, TP53, VEGFA
19pancreatic serous cystadenocarcinoma10.6
20pancreatitis10.4
21peritoneal mesothelioma10.4
22peritonitis10.4
23peritoneal serous adenocarcinoma10.4
24hepatitis10.3
25teratoma10.3
26fallopian tube serous adenocarcinoma10.3
27cervical serous adenocarcinoma10.3
28uterine ligament serous adenocarcinoma10.3
29ovary serous adenocarcinoma10.3
30primary peritoneal carcinoma10.2
31uterine corpus serous adenocarcinoma10.2
32neuroendocrine carcinoma10.2
33large cell neuroendocrine carcinoma10.2
34endocervicitis10.2
35papillary serous adenocarcinoma10.1
36hypoglycemia10.1
37endosalpingiosis10.1
38ovarian endometriosis10.1
39angiosarcoma10.1
40cystic teratoma10.1
41ovarian carcinosarcoma10.1
42plasma cell leukemia10.1
43malignancy diagnosed during pregnancy10.1
44cerebral meningioma10.1PGR
45pericardial effusion10.1MUC16
46ovarian disease10.1CYP19A1, MUC16
47estrogen excess10.1CYP19A1, PGR
48endophthalmitis10.1VEGFA
49progesterone resistance10.1ESR1, PGR
50ovarian cyst10.1CYP19A1, ESR2, MUC16

Graphical network of the top 20 diseases related to Serous Cystadenocarcinoma:



Diseases related to serous cystadenocarcinoma

Symptoms for Serous Cystadenocarcinoma

About this section

Drugs & Therapeutics for Serous Cystadenocarcinoma

About this section
Sources:
6CenterWatch, 43NIH Clinical Center, 7ClinicalTrials, 63UMLS, 42NDF-RT
See all sources

Approved drugs:

Search CenterWatch for Serous Cystadenocarcinoma

Drug clinical trials:

Search ClinicalTrials for Serous Cystadenocarcinoma

Search NIH Clinical Center for Serous Cystadenocarcinoma

Search CenterWatch for Serous Cystadenocarcinoma

Genetic Tests for Serous Cystadenocarcinoma

About this section

Anatomical Context for Serous Cystadenocarcinoma

About this section
Sources:
34MalaCards
See all sources

MalaCards organs/tissues related to Serous Cystadenocarcinoma:

34
Ovary, Pancreas, Colon, Breast, Liver, Bone, Spleen, Lymph node, Testis

Animal Models for Serous Cystadenocarcinoma or affiliated genes

About this section
Sources:
38MGI
See all sources

MGI Mouse Phenotypes related to Serous Cystadenocarcinoma:

38 (show all 27)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00011869.4BCL2, FAS, TP53, CYP19A1
2MP:00053779.2CYP19A1, ESR2, FAS, BCL2, BAX, CDKN1A
3MP:00053758.9CYP19A1, TP53, ESR2, ESR1, AKT1, BCL2
4MP:00053718.6VEGFA, TP53, PGR, ESR2, ESR1, FAS
5MP:00053708.6CYP19A1, VEGFA, TP53, ESR2, ESR1, FAS
6MP:00053918.5VEGFA, TP53, FAS, BCL2, BAX, CDKN1A
7MP:00028738.5PPP2R1A, CYP19A1, VEGFA, TP53, PGR, ESR2
8MP:00053818.5VEGFA, TP53, ESR2, ESR1, FAS, BCL2
9MP:00053888.4VEGFA, TP53, ESR2, ESR1, FAS, AKT1
10MP:00020068.2PPP2R1A, VEGFA, TP53, PGR, ESR2, ESR1
11MP:00053678.1USP2, VEGFA, TP53, ESR2, ESR1, FAS
12MP:00053808.1VEGFA, TP53, PGR, NANOG, ESR1, AKT1
13MP:00053977.8CYP19A1, VEGFA, TP53, PGR, ESR2, ESR1
14MP:00030127.8USP2, VEGFA, TP53, PGR, NANOG, ESR2
15MP:00053877.8ESR2, PGR, TP53, VEGFA, CYP19A1, ESR1
16MP:00053857.7CYP19A1, USP2, VEGFA, TP53, PGR, ESR2
17MP:00053797.6CYP19A1, USP2, VEGFA, TP53, PGR, ESR2
18MP:00053907.5TP53, VEGFA, USP14, CYP19A1, PGR, ESR2
19MP:00053697.5TP53, VEGFA, USP14, CYP19A1, PGR, ESR2
20MP:00107717.4TP53, VEGFA, USP14, CYP19A1, PGR, ESR2
21MP:00036317.3CYP19A1, USP14, VEGFA, TP53, ESR2, ESR1
22MP:00053787.1TP53, VEGFA, USP14, CYP19A1, PPP2R1A, ESR2
23MP:00053896.7CDKN1A, CYP19A1, USP14, USP2, VEGFA, TP53
24MP:00053866.4TP53, VEGFA, USP2, USP14, CYP19A1, PPP2R1A
25MP:00053846.4NANOG, PGR, TP53, VEGFA, USP14, CYP19A1
26MP:00107686.3NANOG, PGR, TP53, VEGFA, USP14, PPP2R1A
27MP:00053766.2TP53, VEGFA, USP2, USP14, CYP19A1, PPP2R1A

Publications for Serous Cystadenocarcinoma

About this section
Sources:
53PubMed
See all sources

Articles related to Serous Cystadenocarcinoma:

(show top 50)    (show all 87)
idTitleAuthorsYear
1
Histological percutaneous diagnosis of stage IV microcystic serous cystadenocarcinoma of the pancreas. (23370947)
2013
2
Serous cystadenocarcinoma of pancreas. (23763806)
2013
3
Ovarian serous cystadenocarcinoma metastasising to the breast. (23445161)
2013
4
Peritoneal papillary serous cystadenocarcinoma at a previous laparoscopic trocar site. (23040941)
2012
5
Serous cystadenocarcinoma of the pancreas: report of a case and management reflections. (22400805)
2012
6
Pancreatic serous cystadenocarcinoma with invasive growth into the colon and spleen. (22066125)
2011
7
Papillary serous cystadenocarcinoma of the stomach, peritoneum and ovary. (20163045)
2009
8
Collision tumor: serous cystadenocarcinoma and dermoid cyst in the same ovary. (18818939)
2009
9
Pancreatic serous cystadenocarcinoma: a case report and review of the literature. (19459016)
2009
10
Serous cystadenocarcinoma of the ovary in an 11-year-old girl with extensive dissemination and chylothorax: a case report and a brief review of literature. (19564753)
2009
11
Serous cystadenocarcinoma of the pancreas with metachronous hepatic metastasis. (19060596)
2008
12
Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma. (18574502)
2008
13
Paratesticular papillary serous cystadenocarcinoma--a case report. (16625973)
2006
14
ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization]. (17160949)
2006
15
Serous cystadenocarcinoma of the pancreas: management of a rare entity. (16025006)
2005
16
Primary papillary serous cystadenocarcinoma of broad ligament. (15845057)
2005
17
Mean nuclear volume in ovarian papillary serous cystadenocarcinoma. (15032078)
2004
18
A primary retroperitoneal serous cystadenocarcinoma with clinically aggressive behavior. (14551796)
2004
19
Plasma cell leukaemia with papillary serous cystadenocarcinoma of ovary--a case report. (15025299)
2003
20
Hepatic resection of metastatic tumor from serous cystadenocarcinoma of the ovary. (12068151)
2002
21
Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. (11201519)
2001
22
Immunohistochemical localization of aromatase and apoptosis-associated proteins in ovarian serous cystadenocarcinoma arising from ovarian endometriosis. (11516810)
2001
23
Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues. (9506768)
1998
24
Prognostic significance of DNA ploidy and S-phase fraction in malignant serous cystadenocarcinoma of the ovary. (9642449)
1998
25
Serous cystadenocarcinoma and ovarian teratoma during pregnancy. (8737305)
1996
26
Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIc serous cystadenocarcinoma of the ovary. (8774651)
1996
27
Serous cystadenocarcinoma of the pancreas. (8968870)
1996
28
Morphologic criteria for the prognosis of serous cystadenocarcinoma of the ovary. (7737584)
1995
29
Stage III papillary serous cystadenocarcinoma of the ovary in a 15-year-old female. (8188094)
1994
30
Papillary serous cystadenocarcinoma arising in benign glandular inclusion cysts in pelvic and inguinal lymph nodes. (9205465)
1994
31
Primary retroperitoneal serous cystadenocarcinoma of 'ovarian-type': US and CT findings. (8223678)
1993
32
Heterophile antigens in serous cystadenocarcinoma of the human ovary. (1283511)
1992
33
A rare case of serous cystadenocarcinoma of the pancreas. (1568167)
1992
34
Successful pregnancy after conservative surgery for ovarian papillary serous cystadenocarcinoma of low malignant potential. (1785199)
1991
35
Establishment and characterization of a human ovarian serous cystadenocarcinoma cell line that produces the tumor markers CA-125 and tissue polypeptide antigen. (2314830)
1990
36
Hyperamylasemia with papillary serous cystadenocarcinoma of the ovary. (2482644)
1989
37
Primary tumor of the rectovaginal septum: mesothelioma or papillary serous cystadenocarcinoma. A case report with transmission electron microscopy. (3668422)
1987
38
An amylase-producing serous cystadenocarcinoma of the ovary. (2409494)
1985
39
Serous cystadenocarcinoma as incidental finding during a repeat cesarean section. (4037003)
1985
40
Cytogenetics of a cell line derived from an ovarian papillary serous cystadenocarcinoma. (6744227)
1984
41
Hyperamylasemia with papillary serous cystadenocarcinoma of the ovary. (6206939)
1984
42
Occurrence of bone in serous cystadenocarcinoma of the ovary. (6816209)
1982
43
Mixed Mullerian tumour of ovary in association with breast carcinoma and serous cystadenocarcinoma carcinoma of other ovary. (6273302)
1981
44
Nature of carcinoembryonic antigen purified from malignant ascitic fluid of serous cystadenocarcinoma of the ovary. (7300840)
1981
45
Classification and survival rate of patients with serous cystadenocarcinoma of the ovaries. (1004656)
1976
46
An immunologic comparison between serous cystadenocarcinoma of the ovary and other human gynecologic tumors. (4126800)
1973
47
Immunologic studies of human serous cystadenocarcinoma of ovary. Demonstration of tumor-associated antigens. (4632680)
1973
48
Hypoglycemia associated with serous cystadenocarcinoma of the ovary. (4189963)
1970
49
Ultrastructure of ovarian tumors. I. Papillary serous cystadenocarcinoma. (4910128)
1970
50
Disseminated endosalpingiosis associated with bilateral papillary serous cystadenocarcinoma of the ovaries. A case report. (13909448)
1962

Variations for Serous Cystadenocarcinoma

About this section

Expression for genes affiliated with Serous Cystadenocarcinoma

About this section
Sources:
2BioGPS, 16Gene Expression Omnibus DataSets
See all sources
Expression patterns in normal tissues for genes affiliated with Serous Cystadenocarcinoma

Search GEO for disease gene expression data for Serous Cystadenocarcinoma.

Pathways for genes affiliated with Serous Cystadenocarcinoma

About this section
Sources:
51PathCards, 39NCBI BioSystems Database, 56Reactome, 54QIAGEN, 52PharmGKB, 61Thomson Reuters, 31KEGG, 62Tocris Bioscience, 13EMD Millipore, 58SinoBiological, 55R&D Systems
See all sources

Pathways related to Serous Cystadenocarcinoma according to GeneCards/GeneDecks:

(show top 50)    (show all 90)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
19.8ESR2, PGR, CYP19A1
29.8AKT1, ESR1, ESR2
3
Show member pathways
9.8TP53, CDKN1A
49.8AKT1, BCL2, BAX
5
Show member pathways
9.8ESR2, ESR1, CYP19A1
6
Show member pathways
9.8BAX, FAS, BCL2
79.8AKT1, ESR1, BCL2
89.7BIRC5, AKT1, TP53
99.6BIRC5, AKT1, BCL2, BAX
10
Show member pathways
FAS pathway and Stress induction of HSP regulation39
Apoptosis and survival FAS signaling cascades61
Caspase cascade in apoptosis39
9.6BAX, FAS, BCL2, AKT1
119.5BAX, BCL2, ESR1, ESR2
12
Show member pathways
IL23-mediated signaling events39
Immune response IL 10 signaling pathway61
Angiopoietin receptor Tie2-mediated signaling39
Development PDGF signaling via STATs and NF kB61
Development Angiopoietin Tie2 signaling61
9.5BIRC5, BCL2, CDKN1A, AKT1
13
Show member pathways
9.5PPP2R1A, AKT1, BCL2, BAX
14
Show member pathways
9.5BCL2, BAX, AKT1, TP53
15
Show member pathways
Prostate Cancer39
Integrated Cancer pathway39
Steroid Biosynthesis39
9.5BCL2, BAX, AKT1, TP53
16
Show member pathways
9.5BCL2, AKT1, BAX, TP53
17
Show member pathways
Cell cycle ESR1 regulation of G1 S transition61
Immune response MIF JAB1 signaling61
Cell cycle Cell cycle generic schema 61
9.4CDKN1A, PGR, AKT1, ESR1
189.4CDKN1A, BCL2, AKT1, VEGFA
199.4AKT1, TP53, BAX, CDKN1A
20
Show member pathways
Immune response IL 4 signaling pathway61
Signal transduction AKT signaling61
9.4TP53, BAX, CDKN1A, AKT1
21
Show member pathways
DNA damage response39
9.4CDKN1A, BAX, FAS, TP53
22
Show member pathways
Prolactin Signaling Pathway39
Development Prolactin receptor signaling61
Leptin signaling pathway39
9.3ESR2, ESR1, BCL2, BAX, AKT1
239.3BAX, TP53, BCL2, CDKN1A
24
Show member pathways
9.3BAX, BCL2, TP53, CDKN1A
25
Show member pathways
9.3CDKN1A, VEGFA, TP53, AKT1
269.3AKT1, CDKN1A, TP53, PPP2R1A
279.3CDKN1A, VEGFA, TP53, BCL2
28
Show member pathways
9.2BCL2, TP53, AKT1, BAX, FAS
29
Show member pathways
Apoptosis and survival TNFR1 signaling pathway61
TWEAK Signaling Pathway39
Apoptosis Modulation by HSP7039
HIV-1 Nef- Negative effector of Fas and TNF-alpha39
9.2BAX, FAS, AKT1, BCL2, TP53
309.2TP53, CDKN1A, BAX, AKT1, BIRC5
319.1CDKN1A, BCL2, FAS, BAX, TP53
32
Show member pathways
Signaling Pathways in Glioblastoma39
9.1CDKN1A, TP53, AKT1, BCL2, VEGFA
33
Show member pathways
9.0AKT1, TP53, FAS, BCL2, BIRC5, BAX
34
Show member pathways
Apoptosis Modulation and Signaling39
Apoptosis39
9.0BCL2, BAX, BIRC5, AKT1, FAS, TP53
35
Show member pathways
Development EGFR signaling via PIP361
Development PDGF signaling via MAPK cascades61
Apoptosis and survival Anti apoptotic action of membrane bound ESR161
Signaling of Hepatocyte Growth Factor Receptor39
Development EGFR signaling via small GTPases61
Development Neurotrophin family signaling61
Apoptosis and survival NGF signaling pathway61
Apoptosis and survival Role of CDK5 in neuronal death and survival61
9.0BAX, BCL2, TP53, AKT1, FAS, ESR1
36
Show member pathways
Signal transduction PTEN pathway61
9.0CDKN1A, TP53, AKT1, BCL2, BIRC5, BAX
37
Show member pathways
Apoptosis and survival Apoptotic TNF family pathways61
8.9BIRC5, BCL2, FAS, TP53, BAX, CDKN1A
38
Show member pathways
8.9BAX, CDKN1A, BCL2, AKT1, FAS, TP53
39
Show member pathways
8.8TP53, AKT1, BAX, BCL2, CDKN1A, PPP2R1A
408.8TP53, CDKN1A, PPP2R1A, VEGFA, AKT1, BCL2
418.7VEGFA, BAX, BCL2, CYP19A1, ESR1, TP53
42
Show member pathways
Proteasome Degradation39
Immune response Antigen presentation by MHC class I61
8.6AKT1, TP53, BAX, BCL2, PPP2R1A, FAS
438.4VEGFA, TP53, FAS, AKT1, BCL2, BIRC5
44
Show member pathways
Toll-like receptor signaling pathway39
Regulation of toll-like receptor signaling pathway39
8.4CDKN1A, BAX, AKT1, TP53, PPP2R1A, BIRC5
45
Show member pathways
8.4AKT1, ESR1, ESR2, PPP2R1A, CDKN1A, TP53
46
Show member pathways
8.4ESR1, ESR2, PPP2R1A, CDKN1A, BCL2, AKT1
47
Show member pathways
8.3VEGFA, PPP2R1A, CDKN1A, BAX, BCL2, AKT1
48
Show member pathways
DNA damage response (only ATM dependent)39
Wnt Signaling Pathway and Pluripotency39
8.2NANOG, TP53, PPP2R1A, AKT1, CDKN1A, BCL2
498.2ESR1, CDKN1A, AKT1, FAS, VEGFA, NANOG
508.2BCL2, BAX, CDKN1A, ESR1, ESR2, TP53

Compounds for genes affiliated with Serous Cystadenocarcinoma

About this section
Sources:
46Novoseek, 12DrugBank, 52PharmGKB, 30IUPHAR, 62Tocris Bioscience, 25HMDB, 3BitterDB
See all sources

Compounds related to Serous Cystadenocarcinoma according to GeneCards/GeneDecks:

(show top 50)    (show all 245)
idCompoundScoreTop Affiliating Genes
1tanshinone iia469.7BCL2, BAX, TP53, FAS
2toremifene46 1210.6FAS, ESR1, ESR2, PGR, CYP19A1
3hoechst 33342469.5BAX, CDKN1A, BCL2, FAS, BIRC5
4trastuzumab46 52 1211.3CYP19A1, VEGFA, FAS, ESR1, BIRC5, PGR
5noxa469.3BAX, CDKN1A, FAS, TP53, BCL2, BIRC5
6suberoylanilide hydroxamic acid469.3TP53, CDKN1A, BAX, BIRC5, BCL2, FAS
73,3-diindolylmethane469.3BAX, BIRC5, ESR1, TP53, VEGFA, CDKN1A
8mifepristone46 30 62 1212.2VEGFA, CYP19A1, ESR1, ESR2, BIRC5, BAX
9cd 437469.2CDKN1A, BCL2, FAS, TP53, BAX
10n-(4-hydroxyphenyl)retinamide469.2ESR1, BCL2, BAX, CDKN1A, CYP19A1, TP53
11celecoxib46 62 30 52 25 1214.2CYP19A1, AKT1, BCL2, BIRC5, VEGFA, BAX
12flavopiridol46 1210.2VEGFA, BIRC5, BAX, CDKN1A, TP53, BCL2
13gefitinib46 52 1211.2ESR1, ESR2, VEGFA, CDKN1A, BIRC5, AKT1
142-chlorodeoxyadenosine469.1FAS, TP53, BCL2, BIRC5, BAX
15bortezomib46 52 1211.1VEGFA, TP53, BCL2, BAX, CDKN1A, BIRC5
16adpribose469.0BCL2, FAS, TP53, BAX, BIRC5, CDKN1A
17sp 60012546 629.9BCL2, AKT1, BAX, CDKN1A, TP53, FAS
18indole-3-carbinol468.9CDKN1A, BAX, BIRC5, BCL2, AKT1, ESR1
19curcumin468.9TP53, BAX, AKT1, BCL2, BIRC5, CDKN1A
20adriamycin468.9PGR, FAS, AKT1, BIRC5, TP53, BCL2
21etoposide46 52 62 1211.9ESR2, FAS, BCL2, BIRC5, BAX, TP53
22gemcitabine46 52 1210.9BAX, BCL2, CDKN1A, CYP19A1, BIRC5, TP53
23thymidylate468.9BAX, FAS, CDKN1A, VEGFA, BCL2, TP53
24egcg468.8VEGFA, TP53, ESR2, FAS, BCL2, BIRC5
25geldanamycin46 52 62 1211.8VEGFA, TP53, PGR, ESR1, BIRC5, CDKN1A
26butyrate468.8CDKN1A, BAX, BCL2, AKT1, FAS, CYP19A1
27taxane468.8CDKN1A, BIRC5, ESR1, PGR, CYP19A1, TP53
28n acetylcysteine468.8TP53, BAX, FAS, AKT1, VEGFA, BCL2
29sb 20358046 629.8VEGFA, AKT1, CDKN1A, BIRC5, TP53, FAS
30cyclophosphamide46 52 1210.7BCL2, MUC16, CYP19A1, VEGFA, TP53, PGR
31arsenite46 259.7BAX, BIRC5, BCL2, AKT1, FAS, PGR
32mg 13246 629.6CDKN1A, BAX, BIRC5, BCL2, AKT1, FAS
33docetaxel46 52 62 1211.6CYP19A1, BIRC5, BCL2, ESR1, PGR, TP53
34ly294002468.5BAX, CDKN1A, BCL2, BIRC5, FAS, VEGFA
35actinomycin d468.4TP53, ESR2, FAS, AKT1, BCL2, BIRC5
36resveratrol46 62 25 1211.4BIRC5, ESR1, ESR2, PGR, TP53, VEGFA
375fluorouracil468.3BIRC5, BAX, CDKN1A, BCL2, FAS, CYP19A1
38retinoid468.3ESR1, BCL2, ESR2, CDKN1A, PGR, TP53
39genistein46 30 62 3 25 1213.3CDKN1A, BAX, BIRC5, BCL2, AKT1, FAS
40h2o2468.3ESR2, BAX, MUC16, TP53, FAS, AKT1
41progesterone46 30 62 25 1212.2ESR2, TP53, CYP19A1, PGR, ESR1, MUC16
42cisplatin46 52 62 1211.2BCL2, BIRC5, BAX, CDKN1A, FAS, MUC16
43retinoic acid46 259.2FAS, ESR1, ESR2, PGR, TP53, CYP19A1
44tamoxifen46 52 30 1211.0BCL2, BIRC5, BAX, CDKN1A, AKT1, CYP19A1
45cycloheximide468.0TP53, PGR, ESR2, ESR1, FAS, AKT1
46paraffin467.8VEGFA, CDKN1A, BAX, BCL2, AKT1, MUC16
47paclitaxel46 52 129.7CYP19A1, VEGFA, TP53, PGR, ESR1, MUC16
48estrogen467.7ESR2, ESR1, PGR, AKT1, BCL2, BIRC5
49doxorubicin46 52 129.5ESR2, BAX, CDKN1A, BIRC5, BCL2, PGR
50vegf467.2FAS, MUC16, ESR1, ESR2, PGR, TP53

GO Terms for genes affiliated with Serous Cystadenocarcinoma

About this section
Sources:
17Gene Ontology
See all sources

Cellular components related to Serous Cystadenocarcinoma according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1pore complexGO:04693010.0BCL2, BAX
2mitochondrial outer membraneGO:0057419.8BAX, BCL2, PGR
3membraneGO:0160208.9PPP2R1A, CYP19A1, VEGFA, ESR1, BCL2
4cytosolGO:0058298.3PPP2R1A, TP53, FAS, AKT1, BCL2, BIRC5
5nucleoplasmGO:0056547.5CDKN1A, RSF1, TP53, PGR, NANOG, ESR2
6nucleusGO:0056346.4NANOG, TP53, USP2, RSF1, PPP2R1A, ESR2

Biological processes related to Serous Cystadenocarcinoma according to GeneCards/GeneDecks:

(show top 50)    (show all 55)
idNameGO IDScoreTop Affiliating Genes
1activation-induced cell death of T cellsGO:00692410.4AKT1, FAS
2regulation of nitrogen utilizationGO:00680810.4BAX, BCL2
3transformed cell apoptotic processGO:00692710.4FAS, BAX
4regulation of protein heterodimerization activityGO:04349710.4BCL2, BAX
5regulation of protein homodimerization activityGO:04349610.4BCL2, BAX
6endoplasmic reticulum calcium ion homeostasisGO:03246910.4BAX, BCL2
7uterus developmentGO:06006510.4ESR2, ESR1
8renal system processGO:00301410.4FAS, BCL2
9response to acidGO:00110110.3BCL2, BAX
10B cell lineage commitmentGO:00232610.3BCL2, TP53
11vagina developmentGO:06006810.2ESR2, ESR1, BAX
12positive regulation of protein oligomerizationGO:03246110.2TP53, BAX
13positive regulation of nitric-oxide synthase activityGO:05100010.2AKT1, ESR1
14negative regulation of cysteine-type endopeptidase activity involved in apoptotic processGO:04315410.2VEGFA, AKT1, BIRC5
15extrinsic apoptotic signaling pathway via death domain receptorsGO:00862510.2BAX, BCL2, FAS
16extrinsic apoptotic signaling pathway in absence of ligandGO:09719210.2FAS, BCL2, BAX
17positive regulation of extrinsic apoptotic signaling pathway in absence of ligandGO:200124110.2PPP2R1A, FAS, BAX
18negative regulation of apoptotic signaling pathwayGO:200123410.2BCL2, BAX
19response to salt stressGO:00965110.2BAX, TP53
20regulation of mitochondrial membrane permeabilityGO:04690210.1BCL2, TP53
21mitotic cell cycle arrestGO:07185010.1TP53, CDKN1A
22positive regulation of peptidyl-serine phosphorylationGO:03313810.1BCL2, AKT1, VEGFA
23mammary gland alveolus developmentGO:06074910.1ESR1, VEGFA
24positive regulation of sequence-specific DNA binding transcription factor activityGO:05109110.1ESR2, ESR1, AKT1
25positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathwayGO:190074010.1TP53, AKT1, BCL2
26release of cytochrome c from mitochondriaGO:00183610.1BAX, BCL2, TP53
27response to gamma radiationGO:01033210.1BAX, BCL2, TP53
28negative regulation of autophagyGO:01050710.1AKT1, BCL2
29positive regulation of intrinsic apoptotic signaling pathwayGO:200124410.1TP53, BCL2, BAX
30neuron apoptotic processGO:05140210.1BAX, BCL2, TP53
31cellular response to organic substanceGO:07131010.0BAX, BCL2
32negative regulation of gene expressionGO:01062910.0PGR, ESR1, CDKN1A
33cellular response to glucose starvationGO:04214910.0TP53, BCL2
34androgen metabolic processGO:00820910.0CYP19A1, ESR1
35ovarian follicle developmentGO:00154110.0VEGFA, ESR2, BCL2, BAX
36response to toxic substanceGO:0096369.9CDKN1A, BAX, BCL2, FAS
37cellular response to hypoxiaGO:0714569.8VEGFA, TP53, AKT1, BCL2
38positive regulation of apoptotic processGO:0430659.8BAX, AKT1, FAS, TP53
39response to ischemiaGO:0029319.8TP53, BCL2
40protein complex assemblyGO:0064619.8PPP2R1A, TP53, FAS
41positive regulation of blood vessel endothelial cell migrationGO:0435369.7AKT1, VEGFA
42intrinsic apoptotic signaling pathwayGO:0971939.6CDKN1A, BAX, BCL2, AKT1, TP53
43positive regulation of mitotic cell cycleGO:0459319.6BIRC5, NANOG, USP2
44gene expressionGO:0104679.6PPP2R1A, PGR, ESR2, ESR1, AKT1
45negative regulation of cell growthGO:0303089.5PPP2R1A, TP53, ESR2, BCL2, CDKN1A
46apoptotic processGO:0069159.2PPP2R1A, TP53, FAS, AKT1, BCL2, BIRC5
47negative regulation of apoptotic processGO:0430669.1VEGFA, TP53, FAS, AKT1, BCL2, BIRC5
48positive regulation of transcription from RNA polymerase II promoterGO:0459449.0VEGFA, TP53, NANOG, ESR1, AKT1
49negative regulation of transcription from RNA polymerase II promoterGO:0001228.9USP2, VEGFA, TP53, NANOG, ESR2
50regulation of transcription, DNA-templatedGO:0063558.7PPP2R1A, TP53, NANOG, ESR2, ESR1, ZNF217

Molecular functions related to Serous Cystadenocarcinoma according to GeneCards/GeneDecks:

(show all 15)
idNameGO IDScoreTop Affiliating Genes
1estrogen response element bindingGO:03405610.2ESR1, ESR2
2BH3 domain bindingGO:05143410.2BAX, BCL2
3estrogen receptor activityGO:03028410.2ESR1, ESR2
4nitric-oxide synthase regulator activityGO:03023510.1ESR1, AKT1
5channel activityGO:01526710.1BAX, BCL2
6steroid bindingGO:00549610.0ESR1, ESR2, PGR
7steroid hormone receptor activityGO:00370710.0PGR, ESR2, ESR1
8core promoter sequence-specific DNA bindingGO:0010469.9ESR1, ESR2
9cyclin bindingGO:0303329.6CDKN1A, USP2
10protein phosphatase 2A bindingGO:0517219.6BCL2, TP53
11enzyme bindingGO:0198999.3TP53, PGR, ESR2, ESR1, AKT1, BIRC5
12protein heterodimerization activityGO:0469829.2PPP2R1A, VEGFA, TP53, BCL2, BIRC5, BAX
13zinc ion bindingGO:0082708.7RSF1, TP53, PGR, ESR2, ESR1, BIRC5
14identical protein bindingGO:0428028.3USP2, VEGFA, TP53, ESR1, FAS, AKT1
15protein bindingGO:0055154.6CDKN1A, PPP2R1A, RSF1, USP14, USP2, VEGFA

Products for genes affiliated with Serous Cystadenocarcinoma

About this section
  • Antibodies
  • Proteins
  • Lysates
  • Antibodies

Sources for Serous Cystadenocarcinoma

About this section
4CDC
14ExPASy
15FMA
23GTR
24HGMD
25HMDB
26ICD10
27ICD10 via Orphanet
28ICD9CM
30IUPHAR
31KEGG
36MeSH
37MESH via Orphanet
38MGI
41NCIt
42NDF-RT
45NINDS
46Novoseek
48OMIM
49OMIM via Orphanet
53PubMed
54QIAGEN
60SNOMED-CT via Orphanet
63UMLS
64UMLS via Orphanet